Predictors of Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Most meta-analyses of risk factors for severe or critical outcomes in patients with COVID-19 only included studies conducted in China and this causes difficulties in generalization. Therefore, this study aimed to systematically evaluate the risk factors in patients with COVID-19 from various countries. Methods: PubMed, Embase, and Web of Science were searched for studies published on the mortality risk in patients with COVID-19 from January 1 to May 7, 2020. Pooled estimates were calculated as odds ratio (OR) with 95% confidence interval (CI) using the random-effects model. Results: We analyzed data from seven studies involving 26,542 patients in total in this systematic review and meta-analysis. Among the patients, 2,337 deaths were recorded (8.8%). Elderly patients and males showed significantly higher mortality rates than young patients and females; the OR values were 3.6 (95% CI 2.5-5.1) and 1.2 (95% CI 1.0-1.3), respectively. Among comorbidities, hypertension (OR 2.3, 95% CI 1.1-4.6), diabetes (OR 2.2, 95% CI 1.2-3.9), cardiovascular disease (OR 3.1, 95% CI 1.5-6.3), chronic obstructive pulmonary disease (OR 4.4, 95% CI 1.7-11.5), and chronic kidney disease (OR 4.2, 95% CI 2.0-8.6) were significantly associated with increased mortalities. Conclusion: This meta-analysis, involving a huge global sample, employed a systematic method for synthesizing quantitative results of studies on the risk factors for mortality in patients with COVID-19. It is helpful for clinicians to identify patients with poor prognosis and improve the allocation of health resources to patients who need them most.
Abstract
Background: Most meta-analyses of risk factors for severe or critical outcomes in patients with COVID-19 only included studies conducted in China and this causes difficulties in generalization. Therefore, this study aimed to systematically evaluate the risk factors in patients with COVID-19 from various countries. Methods: PubMed, Embase, and Web of Science were searched for studies published on the mortality risk in patients with COVID-19 from January 1 to May 7, 2020. Pooled estimates were calculated as odds ratio (OR) with 95% confidence interval (CI) using the random-effects model. Results: We analyzed data from seven studies involving 26,542 patients in total in this systematic review and meta-analysis. Among the patients, 2,337 deaths were recorded (8.8%). Elderly patients and males showed significantly higher mortality rates than young patients and females; the OR values were 3.6 (95% CI 2.5-5.1) and 1.2 (95% CI 1.0-1.3), respectively. Among comorbidities, hypertension (OR 2.3, 95% CI 1.1-4.6), diabetes (OR 2.2, 95% CI 1.2-3.9), cardiovascular disease (OR 3.1, 95% CI 1.5-6.3), chronic obstructive pulmonary disease (OR 4.4, 95% CI 1.7-11.5), and chronic kidney disease (OR 4.2, 95% CI 2.0-8.6) were significantly associated with increased mortalities. Conclusion: This meta-analysis, involving a huge global sample, employed a systematic method for synthesizing quantitative results of studies on the risk factors for mortality in patients with COVID-19. It is helpful for clinicians to identify patients with poor prognosis and improve the allocation of health resources to patients who need them most.
참고문헌 (46)
- "Coronavirus disease (COVID-19) situation dashboard"[URL]
- Chan-Yeung M, "SARS : epidemiology", Respirology, 8(Suppl), pp.S9~S14 (2003)
- "Middle east respiratory syndrome coronavirus (MERSCoV)" (2019)[URL]
- Torres-Salinas, D, "Daily growth rate of scientific production on Covid-19. Analysis in databases and open access repositories", arXiv preprint arXiv:2004.06721, ~ (2004)
- Zheng Z, "Risk factors of critical & mortal COVID-19 cases : A systematic literature review and meta-analysis", J Infect, 81(2), pp.e16~e25 (2020)
- Wang B, "Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis", Aging(Albany NY), 12(7), pp.6049~6057 (2020)
- Henry BM, "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis", Clin Chem Lab Med, 58(7), pp.1021~1028 (2020)
- Stang A, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses", Eur J Epidemiol, 25(9), pp.603~605 (2010)
- Dersimonian R, "Meta-analysis in clinical trials", Control Clin Trials, 7(3), pp.177~188 (1986)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", PLoS Med, 6(7), pp.e1000097~ (2009)
- Grasselli G, "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy", JAMA, 323(16), pp.1574~1581 (2020)
- Guan WJ, "Comorbidity and its impact on 1590 patients with Covid-19 in China : A nationwide analysis", Eur Respir J, 55(5), pp.2000547~ (2020)
- Mehra MR, "Cardiovascular disease, drug therapy, and mortality in Covid-19", N Engl J Med, 382(25), pp.e102~ (2020)
- Miyashita H, "Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City", Ann Oncol, 31(8), pp.1088~1089 (2020)
- Nikpouraghdam M, "Epidemiological characteristics of coronavirus disease 2019(COVID-19)patients in IRAN : A single center study", J Clin Virol, 127, pp.104378~ (2020)
- Richardson S, "Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area", JAMA, 323(20), pp.2052~2059 (2020)
- Tomlins J, "Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease(COVID-19), the first UK cohort", J Infect, 81(2), pp.e59~e61 (2020)
- Choi KW, "Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong", Ann Intern Med, 139(9), pp.715~723 (2003)
- Hong KH, "Predictors of mortality in Middle East respiratory syndrome(MERS)", Thorax, 73(3), pp.286~289 (2018)
- Opal SM, "The immunopathogenesis of sepsis in elderly patients", Clin Infect Dis, 41(Suppl 7), pp.S504~S512 (2005)
- Jin JM, "Higher severity and mortality in male patients with COVID-19 independent of age and susceptibility", Front Public Health, 8, pp.152~ (2020)
- Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181(2), pp.271~280.e8 (2020)
- Yang JK, "Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes", Acta Diabetol, 47(3), pp.193~199 (2010)
- Yang JK, "Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS", Diabet Med, 23(6), pp.623~628 (2006)
- Patel S, "Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?", Clin Exp Pharmacol Physiol, 40(8), pp.551~559 (2013)
- Chu KH, "Acute renal impairment in coronavirus-associated severe acute respiratory syndrome", Kidney Int, 67(2), pp.698~705 (2005)
- Diao B, "Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection", medRxiv 2020:2020.03.04.20031120, ~ (2020)
- Sharif M, "Immune disorders in hemodialysis patients", Iran J Kidney Dis, 9(2), pp.84~96 (2015)
- van Dijk P, "Renal replacement therapy in Europe : the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries", Nephrol Dial Transplant, 16(6), pp.1120~1129 (2001)
- Foley R, "Clinical epidemiology of cardiovascular disease in chronic renal disease", Am J Kidney Dis, 32(5 Suppl 3), pp.S112~S119 (1998)
- Sarnak M, "Mortality caused by sepsis in patients with endstage renal disease compared with the general population", Kidney Int, 58(4), pp.1758~1764 (2000)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study", Lancet, 395(10229), pp.1054~1062 (2020)
- Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, 180(7), pp.934~943 (2020)
- Schiffrin EL, "Hypertension and COVID-19", Am J Hypertens, 33(5), pp.373~374 (2020)
- "HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19"[URL]
- Banik GR, "Risk factors for severity and mortality in patients with MERS-CoV : Analysis of publicly available data from Saudi Arabia", Virol Sin, 31(1), pp.81~84 (2016)
- Knapp S, "Diabetes and infection : Is there a link?-A mini-review", Gerontology, 59(2), pp.99~104 (2013)
- Geerlings S, "Immune dysfunction in patients with diabetes mellitus(DM)", FEMS Immunol Med Microbiol, 26(3-4), pp.259~265 (1999)
- Xiong TY, "Coronaviruses and the cardiovascular system : acute and long-term implications", Eur Heart J, 41(19), pp.1798~1800 (2020)
- Li B, "Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China", Clin Res Cardiol, 109(5), pp.531~538 (2020)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395(10223), pp.497~506 (2020)
- Guo T, "Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019(COVID-19)", JAMA Cardiol, 5(7), pp.811~818 (2020)
- Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323(11), pp.1061~1069 (2020)
- Oudit GY, "SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS", Eur J Clin Invest, 39(7), pp.618~625 (2009)
- Saetta M, "Cellular and structural bases of chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 163(6), pp.1304~1309 (2001)
- Leung JM, "The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD", Respirology, 22(4), pp.634~650 (2017)